Rocket Pharmaceuticals (RCKT)
(Delayed Data from NSDQ)
$21.98 USD
-0.12 (-0.54%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $21.97 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Income Statements
Fiscal Year end for Rocket Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 260 | 224 | 167 | 134 | 76 |
Income After Depreciation & Amortization | -260 | -224 | -167 | -134 | -76 |
Non-Operating Income | 16 | 4 | 1 | 2 | 5 |
Interest Expense | 2 | 2 | 3 | 7 | 6 |
Pretax Income | -246 | -222 | -169 | -140 | -77 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -246 | -222 | -169 | -140 | -77 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -246 | -222 | -169 | -140 | -77 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -253 | -218 | -162 | -133 | -76 |
Depreciation & Amortization (Cash Flow) | 7 | 6 | 5 | 1 | 0 |
Income After Depreciation & Amortization | -260 | -224 | -167 | -134 | -76 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 84.01 | 68.15 | 63.24 | 55.44 | 49.01 |
Diluted EPS Before Non-Recurring Items | -2.92 | -3.26 | -2.67 | -2.52 | -1.58 |
Diluted Net EPS (GAAP) | -2.92 | -3.26 | -2.67 | -2.52 | -1.58 |
Fiscal Year end for Rocket Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 63.28 | 65.43 | 68.75 | 62.19 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -63.28 | -65.43 | -68.75 | -62.19 |
Non-Operating Income | NA | 4.09 | 4.00 | 3.52 | 4.33 |
Interest Expense | NA | 0.47 | 0.47 | 0.47 | 0.47 |
Pretax Income | NA | -59.66 | -61.90 | -65.70 | -58.34 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -59.66 | -61.90 | -65.70 | -58.34 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -59.66 | -61.90 | -65.70 | -58.34 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 93.34 | 82.64 | 80.47 | 79.45 |
Diluted EPS Before Non-Recurring Items | NA | -0.64 | -0.75 | -0.82 | -0.73 |
Diluted Net EPS (GAAP) | NA | -0.62 | -0.75 | -0.82 | -0.73 |